Vermillion Receives $1M in Settlement; Moves to Nasdaq Capital Market | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion disclosed today a settlement agreement that will provide the company with $1 million.

It also said that its stock has been moved to the Nasdaq Capital Market effective Feb. 15.

In a document filed with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it has settled with an unnamed third party over Vermillion's losses on short- and long-term investments in previous years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.